Key result
The PAI-1 4G/4G genotype was associated with a greater risk of thrombosis in symptomatic thrombophilia patients (OR 2.85; 95% CI 1.26-6.46) and in idiopathic DVT patients (OR 3.1; 95% CI 1.26-7.59).
Why the study?
Does the PAI-1 4G/5G polymorphism increase the risk of deep vein thrombosis in patients with inherited thrombophilia?
Population
314 subjects: 149 patients with inherited thrombophilia, 67 patients with idiopathic deep vein thrombosis…
Comparison
PAI-1 gene 4G/5G polymorphism vs Healthy controls and non-4G/4G genotypes
Design
Case-control
Authors
Loading...
Hypothesis-generating for PAI-1 4G/4G in thrombophilia; prospective validation needed before clinical adoption.
Case-Control (n=314)
Does the PAI-1 4G/5G polymorphism increase the risk of deep vein thrombosis in patients with inherited thrombophilia?
Odds Ratio: 2.85 (95% CI 1.26–6.46)
p-value: p=0.01
The PAI-1 4G/4G genotype is associated with higher PAI-1 levels and an increased risk of deep vein thrombosis in patients with inherited thrombophilia and idiopathic DVT.
Sartori et al. (2003) conducted a case-control in Inherited thrombophilia and idiopathic deep vein thrombosis (n=314). PAI-1 gene 4G/4G genotype vs. Controls (healthy subjects) was evaluated on Risk of thrombosis in symptomatic thrombophilia patients (OR 2.85, 95% CI 1.26-6.46, p=0.01). The PAI-1 4G/4G genotype was associated with a greater risk of thrombosis in symptomatic thrombophilia patients (OR 2.85; 95% CI 1.26-6.46) and in idiopathic DVT patients (OR 3.1; 95% CI 1.26-7.59).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: